HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank

被引:0
作者
Rosa Mendez
Natalia Aptsiauri
Ana Del Campo
Isabel Maleno
Teresa Cabrera
Francisco Ruiz-Cabello
Federico Garrido
Angel Garcia-Lora
机构
[1] Hospital Universitario Virgen de las Nieves,Departamento de Análisis Clínicos
[2] Universidad de Granada,Departamento de Bioquímica, Biologia Molecular e Inmunología III
来源
Cancer Immunology, Immunotherapy | 2009年 / 58卷
关键词
HLA class I and II; Melanoma; ESTDAB; Tumour;
D O I
暂无
中图分类号
学科分类号
摘要
Altered HLA class I and class II cell surface expression has been reported in many types of malignancy and represents one of the major mechanism by which tumour cells escape from T lymphocytes. In this report, we review the results obtained from the study of constitutive and IFN-gamma-induced expression of HLA class I and II molecules in 91 human melanoma cell lines from the European Searchable Tumour Cell Line Database, and compare them with published data on HLA expression in other types of cancer. Various types of alterations in HLA class I cell surface expression were found in a high percentage (67%) of the studied cell lines. These alterations range from total to selective HLA class I loss and are associated with β2-microglobulin gene mutations, transcriptional downregulation of HLA class I genes and antigen processing machinery components, or with the loss of heterozygosity in chromosome 6. The most frequently observed phenotype is selective downregulation of HLA-B locus, reversible after treatment with IFN-gamma. The expression of constitutive- or IFN-gamma induced-surface expression of at least one HLA class II locus is positive in 71.5% of the analysed cell lines. Four different HLA class II expression phenotypes were defined, and a positive correlation between the expression of class I and II molecules is discussed. More detailed information on the HLA expression patterns and others immunological characteristics of these melanoma cell lines can be found on the following website http://www.ebi.ac.uk/ipd/estdab.
引用
收藏
页码:1507 / 1515
页数:8
相关论文
共 384 条
[1]  
Altomonte M(2003)Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach? Oncogene 22 6564-6569
[2]  
Fonsatti E(2006)Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients Cancer Res 66 6405-6411
[3]  
Visintin A(2008)Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations Cancer Immunol Immunother 57 1727-1733
[4]  
Maio M(1998)Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides Tissue Antigens 52 520-529
[5]  
Anichini A(2000)CD4(+) T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide in vitro Cancer Immunol Immunother 48 621-626
[6]  
Mortarini R(1995)Biological implications of HLA-DR expression in tumours Scand J Immunol 41 398-406
[7]  
Nonaka D(1996)High frequency of altered HLA class I phenotypes in invasive breast carcinomas Hum Immunol 50 127-134
[8]  
Molla A(2007)HLA class I expression in metastatic melanoma correlates with tumour development during autologous vaccination Cancer Immunol Immunother 56 709-717
[9]  
Vegetti C(2006)Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas Clin Cancer Res 12 4163-4170
[10]  
Montaldi E(2006)Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells J Immunol 177 3100-3107